Rockefeller Capital Management’s VanEck Biotech ETF BBH Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$2.23M Hold
11,862
﹤0.01% 1260
2025
Q4
$2.25M Buy
11,862
+1
+0% +$185 ﹤0.01% 1198
2025
Q3
$1.97M Buy
11,861
+50
+0.4% +$8.15K ﹤0.01% 1171
2025
Q2
$1.81M Buy
11,811
+294
+3% +$43.8K ﹤0.01% 1143
2025
Q1
$1.81M Hold
11,517
﹤0.01% 1075
2024
Q4
$1.81M Hold
11,517
﹤0.01% 1046
2024
Q3
$2.04M Hold
11,517
0.01% 985
2024
Q2
$1.94M Hold
11,517
0.01% 984
2024
Q1
$1.92M Buy
11,517
+25
+0.2% +$4.14K 0.01% 1021
2023
Q4
$1.9M Hold
11,492
0.01% 933
2023
Q3
$1.79M Sell
11,492
-298
-3% -$47.6K 0.01% 885
2023
Q2
$1.84M Buy
11,790
+298
+3% +$47.6K 0.01% 876
2023
Q1
$1.86M Sell
11,492
-230
-2% -$37.2K 0.01% 839
2022
Q4
$1.87M Buy
11,722
+230
+2% +$36.4K 0.01% 771
2022
Q3
$1.62M Buy
11,492
+100
+0.9% +$15.1K 0.01% 835
2022
Q2
$1.66M Hold
11,392
0.01% 825
2022
Q1
$1.85M Hold
11,392
0.01% 824
2021
Q4
$2.16M Hold
11,392
0.01% 769
2021
Q3
$2.3M Hold
11,392
0.01% 718
2021
Q2
$2.3M Hold
11,392
0.01% 686
2021
Q1
$2M Hold
11,392
0.01% 577
2020
Q4
$1.93M Hold
11,392
0.01% 525
2020
Q3
$1.85M Hold
11,392
0.02% 451
2020
Q2
$1.86M Hold
11,392
0.02% 409
2020
Q1
$1.46M Buy
11,392
+42
+0.4% +$5.66K 0.02% 399
2019
Q4
$1.58M Buy
11,350
+10
+0.1% +$1.31K 0.02% 384
2019
Q3
$1.34M Hold
11,340
0.02% 345
2019
Q2
$1.46M Hold
11,340
0.02% 293
2019
Q1
$1.46M Hold
11,340
0.02% 310
2018
Q4
$1.26M Buy
+11,340
New +$1.37M 0.02% 221

Other funds holding BBH

Rockefeller Capital Management's BBH Position: Q1 2026 in Review

Rockefeller Capital Management held its VanEck Biotech ETF (BBH) position steady in Q1 2026 at 11,862 shares worth $2.23M. The position accounts for ﹤0.01% of the portfolio, ranked #1260.

Rockefeller Capital Management first reported a position in BBH in Q4 2018 and has held it in 30 quarters since. The position peaked at $2.3M in Q3 2021. 112 funds tracked by Wall St. Rank hold BBH as of Q1 2026.

  • Rockefeller Capital Management held 11,862 shares of VanEck Biotech ETF worth $2.23M as of Q1 2026.
  • Rockefeller Capital Management left its VanEck Biotech ETF share count unchanged in Q1 2026.
  • VanEck Biotech ETF made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q1 2026, its #1260 holding.
  • Rockefeller Capital Management first reported a position in VanEck Biotech ETF in Q4 2018 and has held it in 30 quarters since.
  • Rockefeller Capital Management's VanEck Biotech ETF position peaked at $2.3M in Q3 2021.
  • 112 funds tracked by Wall St. Rank held VanEck Biotech ETF as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.